BioSpace News Archive

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

The Company also announced an increase in the Aggregate Maximum Purchase Price from $1.5 billion to an amount sufficient to purchase all of the Maximum Tender Offer Notes at Acceptance Priority Levels 1 through 2, as set forth in the second table below, that were validly tendered and not validly withdrawn prior to the Early Tender Date.

HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced that full results from its first-in-human (FIH) clinical study of the Amplifi™ Vein Dilation System were presented at the 2021 VEITH Symposium.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced the completion of a positive safety review and enrollment of the last cohort of subjects at the highest dose level in the Company’s second study of its Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.

AmMax Bio, Inc. today announced that it will host a key opinion leader (KOL) webinar on AMB-05X on Tuesday, December 7th @ 1pm ET

Spectral Medical Inc. and its wholly-owned subsidiary Dialco Medical Inc., announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical update and discuss the latest business developments.

ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, announced the appointment of Marty Lorenzo as General Counsel.

OncoHost, announced today that Professor David R. Gandara, director of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), professor of medicine and senior adviser to the cancer center director, has joined the company’s scientific advisory board.